Galectin Therapeutics Stock Price To Earnings To Growth

GALT Stock

USD 2.89 0.05 1.76%

Galectin Therapeutics fundamentals help investors to digest information that contributes to Galectin Therapeutics' financial success or failures. It also enables traders to predict the movement of Galectin Stock. The fundamental analysis module provides a way to measure Galectin Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Galectin Therapeutics stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Galectin Therapeutics Company Price To Earnings To Growth Analysis

Galectin Therapeutics' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.

PEG Ratio

PE Ratio

EPS Growth

More About Price To Earnings To Growth | All Equity Analysis

Galectin Price To Earnings To Growth Driver Correlations

Understanding the fundamental principles of building solid financial models for Galectin Therapeutics is extremely important. It helps to project a fair market value of Galectin Stock properly, considering its historical fundamentals such as Price To Earnings To Growth. Since Galectin Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Galectin Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Galectin Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Receivables	Net Tangible Assets	Capital Surpluse	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.25	-0.32	-0.5	0.25	0.2	1.0	-0.51	0.68	-0.03	-0.46	0.01	0.33	0.69	0.79	0.78	-0.67
Total Stockholder Equity	0.25		-0.99	0.55	-0.83	-0.89	0.26	-0.11	-0.22	0.31	0.03	0.75	0.94	-0.27	0.06	0.12	0.35
Net Debt	-0.32	-0.99		-0.52	0.8	0.86	-0.33	0.18	0.18	-0.26	-0.03	-0.77	-0.94	0.23	-0.09	-0.15	-0.32
Retained Earnings	-0.5	0.55	-0.52		-0.83	-0.8	-0.49	0.39	-0.89	0.24	0.6	0.58	0.56	-0.89	-0.6	-0.54	0.83
Accounts Payable	0.25	-0.83	0.8	-0.83		0.97	0.24	-0.04	0.56	-0.26	-0.34	-0.86	-0.7	0.61	0.39	0.33	-0.71
Total Liab	0.2	-0.89	0.86	-0.8	0.97		0.19	-0.11	0.52	-0.31	-0.25	-0.83	-0.78	0.57	0.33	0.27	-0.68
Total Current Assets	1.0	0.26	-0.33	-0.49	0.24	0.19		-0.51	0.67	-0.03	-0.45	0.02	0.34	0.68	0.79	0.78	-0.66
Short Term Debt	-0.51	-0.11	0.18	0.39	-0.04	-0.11	-0.51		-0.42	0.55	0.47	-0.1	-0.02	-0.33	-0.34	-0.35	0.25
Common Stock	0.68	-0.22	0.18	-0.89	0.56	0.52	0.67	-0.42		0.01	-0.56	-0.21	-0.28	0.99	0.76	0.71	-0.86
Property Plant Equipment	-0.03	0.31	-0.26	0.24	-0.26	-0.31	-0.03	0.55	0.01		0.32	0.19	0.33	0.04	0.27	0.3	-0.04
Current Deferred Revenue	-0.46	0.03	-0.03	0.6	-0.34	-0.25	-0.45	0.47	-0.56	0.32		0.2	0.11	-0.5	-0.3	-0.28	0.34
Net Receivables	0.01	0.75	-0.77	0.58	-0.86	-0.83	0.02	-0.1	-0.21	0.19	0.2		0.57	-0.26	-0.22	-0.2	0.43
Net Tangible Assets	0.33	0.94	-0.94	0.56	-0.7	-0.78	0.34	-0.02	-0.28	0.33	0.11	0.57		-0.28	0.13	0.2	0.3
Capital Surpluse	0.69	-0.27	0.23	-0.89	0.61	0.57	0.68	-0.33	0.99	0.04	-0.5	-0.26	-0.28		0.76	0.7	-0.88
Net Invested Capital	0.79	0.06	-0.09	-0.6	0.39	0.33	0.79	-0.34	0.76	0.27	-0.3	-0.22	0.13	0.76		0.99	-0.86
Net Working Capital	0.78	0.12	-0.15	-0.54	0.33	0.27	0.78	-0.35	0.71	0.3	-0.28	-0.2	0.2	0.7	0.99		-0.8
Capital Stock	-0.67	0.35	-0.32	0.83	-0.71	-0.68	-0.66	0.25	-0.86	-0.04	0.34	0.43	0.3	-0.88	-0.86	-0.8

Click cells to compare fundamentals

Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.

Competition

Predict Galectin Therapeutics

Galectin Price Earnings To Growth Ratio

Price Earnings To Growth Ratio

(0.21)

At this time, Galectin Therapeutics' Price Earnings To Growth Ratio is comparatively stable compared to the past year.

Based on the latest financial disclosure, Galectin Therapeutics has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 100.0% higher than that of the company.

Galectin Price To Earnings To Growth Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Galectin Therapeutics' direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Galectin Therapeutics could also be used in its relative valuation, which is a method of valuing Galectin Therapeutics by comparing valuation metrics of similar companies.

Galectin Therapeutics is currently under evaluation in price to earnings to growth category among its peers.

Galectin Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Galectin Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Galectin Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

Galectin Fundamentals

	Return On Equity	-37.28
	Return On Asset	-1.04
	Current Valuation	261.13 M
	Shares Outstanding	62.76 M
	Shares Owned By Insiders	30.95 %
	Shares Owned By Institutions	15.77 %
	Number Of Shares Shorted	5.7 M
	Price To Earning	(4.21) X
	Price To Book	207.70 X
	EBITDA	(202 K)
	Net Income	(41.07 M)
	Cash And Equivalents	15.83 M
	Cash Per Share	0.27 X
	Total Debt	71.81 M
	Current Ratio	1.79 X
	Book Value Per Share	(1.01) X
	Cash Flow From Operations	(32.97 M)
	Short Ratio	42.37 X
	Earnings Per Share	(0.73) X
	Target Price	11.0
	Number Of Employees	14
	Beta	0.63
	Market Capitalization	181.38 M
	Total Asset	28.2 M
	Retained Earnings	(354.37 M)
	Working Capital	12.03 M
	Current Asset	26.4 M
	Current Liabilities	1.36 M
	Net Asset	28.2 M

About Galectin Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Galectin Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Galectin Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Galectin Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Galectin Stock Analysis

When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC